Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19

The COVID-19Dexamethasone (CoDEX) randomized clinical trial was conducted to evaluate the efficacy of intravenous dexamethasone in patients with moderate to severe ARDS due to COVID-19. The hypothesis was that dexamethasone would increase the number of days alive and free from mechanical ventilation during the first 28 days.

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19
Size: 475 KB